Whats in a Number?

Paul, Reid
April 2011
Pharmaceutical Representative;Apr2011, Vol. 41 Issue 4, p5
The author reflects on the criticism to the high costs for pharmaceutical research written in the article of Donald Light and Rebecca Warburton in the U.S. Light and Warburton have been criticized for the inaccurate figures on the cost for pharmaceutical research. He shares that the inability of pharmaceutical firms to determine the cost for drug development explains the inaccurate figures for the research.


Related Articles

  • $43M to Develop a Drug? An Unlikely Conclusion. Thiel, Karl // BioWorld Today;3/16/2011, Vol. 22 Issue 51, p1 

    The article discusses the cost of developing a drug. According to a study by Donald Light of the University of Medicine and Dentistry in Princeton, New Jersey, and Rebecca Warburton of the University of Victoria, the cost of drug development is about 55 million dollars, significantly lower than...

  • Flawed arithmetic on drug development costs. Subbaraman, Nidhi // Nature Biotechnology;May2011, Vol. 29 Issue 5, p381 

    The article discusses a study by researchers Donald W. Light and Rebecca Warburton on the median cost of developing drugs. The study which estimated median drug development cost to be as low as 59 million U.S. dollars has raised concerns. Critics argue that the researchers made the wrong...

  • Honing Reforms from Clinical Development. Stergiopoulos, Steila; Getz, Ken; Soenen, Mike // Pharmaceutical Executive;Feb2011, Vol. 31 Issue 2, p18 

    The article reports on the study carried out by the Tufts Center for Study of Drug Development (Tufts CSDD) and commissioned by Clear Trial which shows the difficulties associated with capacity planning and forecasting methodologies in various biopharmacies and medical device companies in the...

  • An Analysis of US Food and Drug Administration Clinical Hold Orders for Drugs and Biologics: A Prospective Study Between 2008 and 2014. Boudes, Pol // Pharmaceutical Medicine - New Zealand;Aug2015, Vol. 29 Issue 4, p203 

    Introduction: The US Food and Drug Administration (FDA) may issue a clinical hold order during drug development, notably for an unreasonable risk for participating subjects. Holds are important events; however, to date, there has not been a comprehensive study of this topic. The aim of this...

  • The incredible thinking industry. Chase, James // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p6 

    An introduction to the journal is presented wherein the author discusses the topics to be addressed at the Virtual Summit on May 24, 2011 which focus on the pharmaceutical industry in the U.S.

  • REPORTERS Notebook.  // Drug Store News;2/7/2011, Vol. 33 Issue 2, p28 

    The article offers news briefs related to the pharmaceutical industry in the U.S. including the approval of Watson Pharmaceuticals Inc.'s generic drug by the Food and Drug Administration (FDA), the development of biosimilars by Merck & Co. Inc. and the launch of MyEpiPenn, a smart phone...

  • Clinical Briefs. Kuritzky, Louis // Internal Medicine Alert;1/29/2010, Vol. 32 Issue 2, p16 

    The article offers news briefs related to pharmaceutical industry in the U.S. in 2010.

  • MED ED REPORT: Update.  // Medical Marketing & Media;Apr2011, Vol. 46 Issue 4, p19 

    The article offers news briefs related to the pharmaceutical industry in the U.S. including Informed Medical Communications merged with IC Axon, Prime-Med Point of Care launched the website www.pri-medpointofcare.com, and PDI launched its EngageCE division.

  • Three Things.  // Pharmaceutical Representative;Sep2011, Vol. 41 Issue 9, p9 

    The article offers updates in the pharmaceutical industry of the U.S. including the cuts on research & development in Lundbeck Research USA, the use of iPad or tablet computers by physicians, and the spurring of debt-ceiling deals in the industry.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics